Pure Global
NCT01379560

A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

Sucampo Pharma Americas, LLC·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
unoprostone isopropyl
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sucampo Pharma Americas, LLC
Funder
Mallinckrodt
Location
Vienna, Austria
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2011
End date
Dec 01, 2011
Enrollment
33 participants
Primary outcome

Change in choroidal blood flow

Summary

The purpose of this study is to determine the pharmacodynamics of ocular blood flow
 measurements with multiple drop unoprostone isopropyl administration versus placebo in
 subjects with dry age-related macular degeneration (AMD).

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01379560
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01379560 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sucampo Pharma Americas, LLC and is currently Completed. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.